Granules India’s stock declined 4% intraday on September 9 after the company got six observations from the US Food and Drug Administration.
Granules India Limited recently informed exchanges that it has completed a US Food and Drug Administration (USFDA) inspection of its Gagillapur facility in Hyderabad, Telangana. The inspection, which ran from August 26 to September 6, 2024, resulted in six observations.
The company will address the observations as soon as possible and will respond to the USFDA within the stipulated timeframe, it added.
As of 11:05 am, Granules India shares were trading 3.21% lower at Rs 666.00 on the NSE.
